Immune-Mediated Inflammatory Disease (IMID) encompasses a broad category of over 100 related diseases in which the person's immune system attacks his or her own tissue. Pathogenesis is amplified by inflammatory cytokines and is self-perpetuating due to persistence of self-antigens and redundancy in inflammatory pathways. Over the years, the therapeutic goal in IMID has shifted from control of symptoms toward achieving clinical remission and tissue healing in order to prevent disease progression. Monoclonal antibodies (mAbs) have been used either individually or in combinations to combat the mechanisms that drive IMID pathogenesis.